The new K_V3.4 inhibitor BDS-I[1–8] as a potential pharmacological opportunity in Alzheimer’s disease therapy  

作　　者：Ilaria Piccialli Roselia Ciccone Anna Pannaccione 

机构地区：[1]Division of Pharmacology, Department of Neuroscience,Reproductive and Dentistry Sciences, School of Medicine, Federico II University of Naples

出　　处：《Neural Regeneration Research》2020年第7期1255-1256,共2页中国神经再生研究（英文版）

基　　金：supported by the following grants:ProgettoAteneo Federico II to AP;PON03PE_00146_1 by MIUR;POR Campania FESR 2007-2013 MOVIE(B25C1300024007);POR Campania FESR 2007-2013 FARMABIONET(B25C1300023007);ProgrammaOperativo Nazionale(PON_01602 and PON03PE_00146_1)from MIUR

摘　　要：Alzheimer's disease(AD)is the most common neurodegenerative disorder and the first cause of dementia in the elderly,with no treatment able to prevent or to block disease progression.AD is characterized by memory impairment and cognitive dysfunction,followed in the late phases of the disease by severe neurodegeneration and neuronal death.The amyloid-β(Aβ)peptide,generated upon the processing of the amyloid precursor protein,is considered the main initiator of AD pathology.Indeed,Aβpeptides,which aggregate and accumulate to form extracellular plaques and intraneuronal deposits.

关 键 词：inhibitor BDS-I[1-8] BDS Alzheimer 

分 类 号：R74[医药卫生—神经病学与精神病学]